MediWound (NASDAQ:MDWD) Share Price Crosses Above Fifty Day Moving Average - Time to Sell?

MediWound Ltd. (NASDAQ:MDWD - Get Free Report)'s stock price crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $16.88 and traded as high as $18.22. MediWound shares last traded at $18.03, with a volume of 39,218 shares trading hands.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on MDWD. StockNews.com raised shares of MediWound to a "sell" rating in a research note on Friday, March 21st. HC Wainwright reaffirmed a "buy" rating and set a $25.00 target price on shares of MediWound in a report on Thursday, March 20th. Finally, Craig Hallum began coverage on MediWound in a research report on Friday, February 28th. They set a "buy" rating and a $39.00 price target for the company.

MediWound Stock Down 2.5 %

The stock has a market capitalization of $191.30 million, a PE ratio of -6.10 and a beta of 0.50. The company has a 50-day moving average of $16.86 and a 200 day moving average of $17.47.

MediWound (NASDAQ:MDWD - Get Free Report) last issued its earnings results on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $0.23. The business had revenue of $5.84 million during the quarter, compared to the consensus estimate of $5.79 million. MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same period last year, the company earned ($0.19) EPS. As a group, equities analysts predict that MediWound Ltd. will post -2.66 EPS for the current fiscal year.

Institutional Investors Weigh In On MediWound

Hedge funds and other institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC increased its position in MediWound by 1,507.1% during the first quarter. GAMMA Investing LLC now owns 1,816 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 1,703 shares during the last quarter. R Squared Ltd acquired a new stake in MediWound during the fourth quarter worth about $32,000. Russell Investments Group Ltd. increased its position in MediWound by 154.1% during the fourth quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 1,162 shares during the last quarter. Bank of America Corp DE increased its position in MediWound by 38.0% during the fourth quarter. Bank of America Corp DE now owns 7,915 shares of the biopharmaceutical company's stock worth $141,000 after purchasing an additional 2,178 shares during the last quarter. Finally, Rhumbline Advisers increased its position in MediWound by 7.3% during the fourth quarter. Rhumbline Advisers now owns 10,835 shares of the biopharmaceutical company's stock worth $193,000 after purchasing an additional 739 shares during the last quarter. 46.83% of the stock is currently owned by institutional investors and hedge funds.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.